%0 Journal Article
%A Mena-Vazquez, Natalia
%A Rojas-Gimenez, Marta
%A Fuego-Varela, Clara
%A Garcia-Studer, Aimara
%A Perez-Gomez, Nair
%A Romero-Barco, Carmen Maria
%A Godoy-Navarrete, Francisco Javier
%A Manrique-Arija, Sara
%A Gandia-Marinez, Myriam
%A Calvo-Gutierrez, Jerusalem
%A Morales-Garrido, Pilar
%A Mouriño-Rodriguez, Coral
%A Castro-Perez, Patricia
%A Añon-Oñate, Isabel
%A Espildora, Francisco
%A Aguilar-Hurtado, Maria Carmen
%A Hidalgo-Conde, Ana
%A Arnedo-Diez de-Los-Rios, Rocio
%A Cabrera-Cesar, Eva
%A Redondo-Rodriguez, Rocio
%A Velloso-Feijoo, Maria Luisa
%A Fernandez-Nebro, Antonio
%T Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease.
%D 2022
%@ 2227-9059
%U http://hdl.handle.net/10668/20838
%X To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2-42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03-3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70-0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72-0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile.
%K Abatacept
%K Biologics
%K Interstitial lung disease
%K Rheumatoid arthritis
%K AGS - Jerez, Costa Noroeste y Sierra de Cádiz
%K AGS - Sur de Sevilla
%~